A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

BACKGROUND: This phase I, four-arm, open-label study (NCT01347866) evaluated the PI3K/mTOR inhibitors PF-04691502 (arms A, B) and gedatolisib (PF-05212384; arms C, D) in combination with the MEK inhibitor PD-0325901 (arm A, D) or irinotecan (arm B, C) in patients with advanced solid tumors. OBJECTIV...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Target Oncol
Päätekijät: Wainberg, Zev A., Alsina, Maria, Soares, Heloisa P., Braña, Irene, Britten, Carolyn D., Del Conte, Gianluca, Ezeh, Patrick, Houk, Brett, Kern, Kenneth A., Leong, Stephen, Pathan, Nuzhat, Pierce, Kristen J., Siu, Lillian L., Vermette, Jennifer, Tabernero, Josep
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer International Publishing 2017
Aiheet:
Original Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5700209/
https://ncbi.nlm.nih.gov/pubmed/29067643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-017-0530-5
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia